Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 1,568 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control regimen Clear all

Conditions: Obesity, Overweight
Interventions: Tirzepatide, Placebo, Liraglutide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Indianapolis, Indiana • Baton Rouge, Louisiana • Baltimore, Maryland

Conditions: Cirrhosis, Liver, End Stage Liver DIsease, Acute Kidney Injury, Liver Transplant; Complications
Interventions: Angiotensin II, Norepinephrine; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Human Papillomavirus Infections
Interventions: Ad26.HPV16, Ad26.HPV18, MVA.HPV16/18, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 11
States / cities: Doral, Florida • Fort Myers, Florida • Miami, Florida + 8 more

Conditions: Acute Lymphoblastic Leukemia
Interventions: Gross Motor Function, Knee extension strength, Hand grip strength, Flexibility, Ankle range of motion, Aerobic capacity, Body composition and vital signs; Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 5 Years to 10 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 4
States / cities: Portland, Oregon • Philadelphia, Pennsylvania • Memphis, Tennessee + 1 more

Conditions: Rheumatoid Arthritis
Interventions: fostamatinib, placebo, fostamatinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 923 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 41
States / cities: Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more

Conditions: Septic Shock
Interventions: selepressin, placebo; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 868 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 17
States / cities: Colorado Springs, Colorado • Idaho Falls, Idaho • Chicago, Illinois + 13 more

Conditions: Alcohol Withdrawal, Alcohol Withdrawal Delirium
Interventions: Phenobarbital, Lorazepam; Drug
Lead sponsor: OSF Healthcare System; Other
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: Contraception, HIV
Interventions: Levonorgestrel and Ethinyl Estradiol; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Arthritis, Rheumatoid
Interventions: TRU-015, Methylprednisolone, Prednisone; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 29
States / cities: Birmingham, Alabama • Paradise Valley, Arizona • Los Angeles, California + 24 more

Conditions: Crohn Disease
Interventions: JNJ-64304500, Placebo, Ustekinumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 37
States / cities: Lone Tree, Colorado • Coral Gables, Florida • Kissimmee, Florida + 34 more

Conditions: Diabetes Mellitus
Interventions: Texting; Behavioral
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Glaucoma
Interventions: ASP2767, Sham ASP2767, Prophylactic Regimen A, Prophylactic Regimen B, Placebo for prophylactic regimen; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Kidney Transplantation, Diabetes, Hyperglycemia
Interventions: insulin, NPH Insulin or glargine insulin and aspartame insulin; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow, Metastatic Malignant Neoplasm in the Lung, Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Interventions: Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, External Beam Radiation Therapy, Ganitumab, Ifosfamide, Stereotactic Radiosurgery, Therapeutic Surgical Procedure, Vincristine, Vincristine Sulfate; Drug · Radiation · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 50 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 298
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 203 more

Conditions: Wound Healing
Interventions: SoC Adhesive Bandage, Antibiotic Ointment, Antiseptic Wash, Hydrocolloid Pad; Device · Drug
Lead sponsor: Johnson & Johnson Consumer Inc. (J&JCI); Industry
Eligibility: 25 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Richardson, Texas

Conditions: Radius Fracture Distal, Pain, Postoperative
Interventions: Acupuncture; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Infantile Hemangioma
Interventions: Propranolol, Placebo; Drug
Lead sponsor: Pierre Fabre Dermatology; Industry
Eligibility: 35 Days to 150 Days
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 10
States / cities: Irvine, California • Redwood City, California • San Diego, California + 7 more

Conditions: HIV-1-infection
Interventions: GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 12
States / cities: Torrance, California • New Haven, Connecticut • Ft. Pierce, Florida + 8 more

Conditions: Breast Cancer, Breast Carcinoma in Situ, Breast Cancer Female
Interventions: Control Arm ACSM Guidelines, Experimental Arm 6-12-25 repetitions per set; Other
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 20 Years to 89 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Sarcoidosis
Interventions: Antibiotic Regimen, Placebo Regimen; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: HIV Infections
Interventions: Interferon beta-1b, Zidovudine; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 25
States / cities: Berkeley, California • Los Angeles, California • Oakland, California + 13 more

Conditions: Schizophrenia
Interventions: Placebo, Luvadaxistat; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 33
States / cities: Phoenix, Arizona • Bentonville, Arkansas • Bryant, Arkansas + 24 more

Conditions: Adenotonsillectomy, Postoperative Pain
Interventions: Celecoxib, Acetaminophen, Dexamethasone; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 2 Years to 18 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
Interventions: Intensity Modulated Radiotherapy (IMRT), Cisplatin (or alternative), Assessment for surgical evaluation; Radiation · Drug · Procedure
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 4
States / cities: Gainesville, Florida • Jacksonville, Florida • Chapel Hill, North Carolina + 1 more

Search by objective public record fields.

A Study of Tirzepatide in Overweight and Very Overweight Participants

Angiotensin 2 for AKI After OLT

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

Aerobic and Strengthening Exercise for Acute Leukemia

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.

Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial

Phenobarbital vs Ativan for Alcohol Withdrawal in the Intensive Care Unit

Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics

Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis

Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease

Texting for Diabetes

A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage

IV Insulin Protocol in Diabetes and Renal Transplantation

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

A Study to Assess Wound Healing Efficacies of Different Clean, Treat, and Protect Wound Care Regimens Compared to Standard of Care and Untreated

Auricular Acupuncture As Part Of A Multimodal Regimen After Distal Radius Open Reduction and Internal Fixation

Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy

Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment

EXERT-BCH Exercise Regimen to Improve Muscle Mass After Treatment of Breast Cancer

Trial of Antimycobacterial Therapy in Sarcoidosis

Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen

Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia

Preoperative Celecoxib and Acetaminophen Versus Acetaminophen Alone for Pain Control After Pediatric Adenotonsillectomy

P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC